The heterodimeric pre-mRNA splicing factor, U2AF (U2 snRNP auxiliary factor), plays a critical role in 3 splice site selection. Although the U2AF subunits associate in a tight complex, biochemical experiments designed to address the requirement for both subunits in splicing have yielded conflicting results. We have taken a genetic approach to assess the requirement for the Drosophila U2AF heterodimer in vivo. We developed a novel Escherichia coli copurification assay to map the domain on the Drosophila U2AF large subunit (dU2AF 50 ) that interacts with the Drosophila small subunit (dU2AF 38 ). A 28-amino-acid fragment on dU2AF 50 that is both necessary and sufficient for interaction with dU2AF 38 was identified. Using the copurification assay, we scanned this 28-amino-acid interaction domain for mutations that abrogate heterodimer formation. A collection of these dU2AF
Generation of functional mRNA in eukaryotes requires the removal of noncoding sequences (introns) from pre-mRNA by a process termed RNA splicing (17, 24) . Pre-mRNA splicing takes place in the spliceosome, a dynamic RNA-protein complex that assembles in a stepwise, ATP-dependent manner on the pre-mRNA (13, 17) . The spliceosome is composed of small nuclear ribonucleoprotein particles (snRNPs) and extrinsic (non-snRNP) protein factors. The earliest steps in spliceosome assembly involve the specification of the exon and intron boundaries by U1 and U2 snRNP. U1 snRNP binds the 5Ј splice site, and U2 snRNP binds the branch site sequence (13, 17, 19) . Since in most cases the first AG dinucleotide downstream of the branch site is used as the 3Ј splice site, U2 snRNP defines the 3Ј splice site (20, 27) . The branch site sequence in metazoan introns is highly degenerate and is not sufficient for U2 snRNP recognition (22) . Targeting of U2 snRNP to the branch site requires the extrinsic protein factor U2AF (U2 snRNP auxiliary factor). U2AF binds site specifically to the intron pyrimidine tract located between the branch point sequence and the 3Ј splice site and recruits U2 snRNP to the branch site at an early step in spliceosome assembly (22, 36) . Regulation of 3Ј splice site choice, both positive and negative, can be modulated by U2AF binding to the intron pyrimidine tract (3, 6, 17) . Thus, U2AF is a major determinant in 3Ј splice site selection.
Human U2AF is a heterodimer composed of large and small subunits (35) . Homologs of both U2AF subunits have been identified in Drosophila and Schizosaccharomyces pombe (10, 18, 21, 32, 34) . A factor related to the U2AF large subunit, called MUD2p, exists in the budding yeast, Saccharomyces cerevisiae, which appears to have some of the properties of U2AF in terms of its role in branch site selection by U2 snRNP (1, 2, 5) . However, no small subunit equivalent has been found in S. cerevisiae (13, 17) . Human U2AF consists of a 65-kDa large subunit (hU2AF 65 ) (36) and a 35-kDa small subunit (hU2AF 35 ) (37) . The Drosophila U2AF large-and small-subunit homologs are 50 and 38 kDa, respectively (dU2AF 50 and dU2AF 38 ) (11, 21) . The U2AF large subunit contains an amino-terminal arginine-serine-rich domain (RS), a central domain required for interaction with the small subunit, and three RNA recognition motifs (36) .
U2AF can be depleted from nuclear splicing extracts by poly(U)-Sepharose chromatography (34) or anti-hU2AF 35 antibodies (39) . Both extracts are inactive for splicing but seem to have different requirements for reactivation. Reactivation of the poly(U)-depleted extract can be achieved by the addition of recombinant large subunit alone (hU2AF 65 or dU2AF 50 ) (11, 31, 36) . Even though the U2AF large and small subunits, purified from mammalian (or Drosophila) cells, associate in a tight complex, the small subunit appears to be dispensable for splicing in this assay. Recombinant hU2AF 65 lacking the domain required for interaction with hU2AF 35 , as defined by the yeast two-hybrid assay, can also reactivate the poly(U)-depleted extract (7) . Thus, it is unlikely that reactivation by the large subunit alone is a result of association between trace amounts of the small subunit remaining in the poly(U)-depleted extract and the exogenously added recombinant large subunit. Recently, a biochemical requirement for the small subunit in splicing was observed with an extract immunodepleted of U2AF activity with anti-hU2AF 35 antibodies (39) . Partial reactivation of the immunodepleted extract could be achieved by the addition of either recombinant hU2AF 65 or hU2AF 35 . Addition of both subunits reconstituted splicing to a level similar to that of the mock-depleted extract (39) . The reason for the strikingly different requirements for reactivation of splicing in these two U2AF-depleted extracts remains unresolved. Consistent with the requirement for the small subunit observed in the immunodepleted extracts, we have previously shown that dU2AF coding sequence from pRSETA-h65 (11) was subcloned into pRSETAKX between the NdeI and EcoRI sites to create pRSETAKX-h65. The two hU2AF subunit expression plasmids were dimerized as described above.
To create the second coexpression plasmid (the bicistron), the dU2AF 50 cDNA was inserted into pRSETA (Invitrogen) between the BamHI and HindIII sites to create pdr6. Oligonucleotide linkers containing a consensus Shine-Dalgarno sequence and NdeI and PstI restriction sites (top strand, 5Ј AGCTTAG AGGTATTCATATGGAATTCCTGCAG 3Ј; bottom strand, 5Ј AGCTCTGCA GGAATTCCATATGAATACCTCTA 3Ј) were annealed and inserted into the unique HindIII site in pdr6 to create pdr151. The dU2AF 38 cDNA was inserted into pdr151 between the NdeI and PstI sites by partial cleavage of pdr151 to create pdr154.
Creation of point mutations in the dU2AF 50 interaction domain. Point mutations in dU2AF 50 were generated by site-directed mutagenesis with uracil-substituted single-stranded DNA (14) . The following mutagenic oligonucleotides were used: mutant 1, 5Ј GAATCCCGGCGGCGGTGCAGCCGCATAAAGC GACGGCTT 3Ј; mutant 2, 5Ј CGGGGTGATGTGCTCGGCTCCCGCCGCC GGTACATCCCAATAAAG 3Ј; mutant 3, 5Ј GTATTGCATCGGGGTGGCG TGCGCGGCTCCCGGCGGCGGTAC 3Ј; and mutant 4, 5Ј GGACGCCTGC ATGGCTGCGGCTTGCGCCGGGGTGATGTGCTCG 3Ј. Site-directed mutagenesis was performed with single-stranded DNA derived from pdr6. Internal 289-bp XhoI-SphI DNA fragments spanning the interaction domain were sequenced completely to confirm the mutations and subcloned into the bicistron expression vector in a three-way ligation with an SphI-BstEII dU2AF 50 DNA fragment from pdr6 and pdr154 cleaved with XhoI and BstEII to create pdr213 (mutant 1), pdr214 (mutant 2), pdr212 (mutant 3), and pdr211 (mutant 4). The 289 XhoI-SphI DNA fragments were also subcloned into the hemagglutinin (HA)-tagged dU2AF 50 in vivo expression vector (pdr152, see below) in a similar three-way ligation (pdr152 was cleaved with XhoI and BstEII) to create pdr207-210. NotI DNA fragments from pdr152 and pdr207-210 that contained the dU2AF 50 promoter, dU2AF 50 coding sequence and dU2AF 50 3Ј untranslated region were inserted into a unique NotI site in the Drosophila transformation vector pw8 (4) .
Creation of epitope-tagged dU2AF 50 . The HA-tagged dU2AF 50 transgene was created by insertion of an oligonucleotide linker (top strand, 5Ј CTAGCTACC CCTATGACGTGCCGGATTACGCCG 3Ј; bottom strand, 5Ј GATCCGGCG TAATCCGGCACGTCATAGGGGTAG 3Ј) between the NheI and BamHI sites into the dU2AF 50 in vivo expression vector (pdr141) (21c) to generate pdr152.
Expression and copurification of U2AF heterodimers. The U2AF subunits were coexpressed in E. coli BL21 (DE3) pLysS. Cells were grown in Luria broth at 30°C to an optical density at 600 nm at of 0.4, induced by the addition of isopropyl-␤-D-thiogalactopyranoside (IPTG) to 0.5 mM, and harvested after 3 to 4 h. All subsequent manipulations were carried out at 4°C. Cells were harvested by centrifugation and resuspended in buffer I (50 mM Tris-HCl [pH 8.0], 1 M NaCl, 5 mM ␤-mercaptoethanol, 1 mM phenylmethylsulfonyl fluoride [PMSF]). A crude extract was prepared by freeze-thawing the cells, followed by sonication and centrifugation at 30,000 rpm in a Ti70 rotor for 30 min at 4°C. The soluble extract was loaded on an HR5/5 (Pharmacia) Ni 2ϩ -nitrilotriacetic acid (NTA)-agarose (Qiagen) column equilibrated with buffer I containing 10% glycerol. Bound protein was washed with buffer I containing 10% glycerol and 20 mM imidazole and eluted in buffer I containing 10% glycerol and 200 mM imidazole. Peak fractions were pooled and frozen in liquid nitrogen and stored at Ϫ80°C or diluted to 350 mM NaCl with buffer H (20 mM HEPES [pH 7.6], 1 mM EDTA, 0.5 mM dithiothreitol [DTT], 10% glycerol) and further purified on an HR5/5 Mono S column (Pharmacia) equilibrated with buffer H containing 350 mM NaCl. Bound protein was eluted with a linear NaCl gradient from 350 mM to 1.5 M NaCl. dU2AF 50 monomer eluted at ϳ550 mM NaCl, and dU2AF heterodimer eluted at ϳ900 mM NaCl.
Stoichiometry of the purified dU2AF and dU2AF 50 was determined by analytical gel filtration chromatography. Purified proteins (250 g) were loaded onto a Superose 12 column (Pharmacia) equilibrated with 20 mM HEPES-NaOH (pH 7.6), 250 mM KCl, 10% glycerol, 1 mM DTT, 0.2 mM EDTA, 0.05% Nonidet P-40 (NP-40), 1 mM PMSF. Elution profiles were compared to gel filtration standards (Bio-Rad). dU2AF eluted as a heterodimer, and dU2AF 50 eluted as a monomer.
In an attempt to reconstitute dU2AF heterodimers from independent subunit preparations, we mixed individually purified dU2AF 50 and dU2AF 38 at a concentration of 1 mg/ml and dialyzed the solution overnight in buffer A (20 mM HEPES-NaOH [pH 7.6], 400 mM KCl, 10% glycerol, 1 mM DTT, 0.2 mM EDTA, 0.05% NP-40, 1 mM PMSF) or buffer A with 6 M guanidine-HCl and dialyzed in steps (6, 4, 2, 1, 0.5, and 0 M guanidine-HCl). Heterodimer formation was assayed by coimmunoprecipitation with anti-dU2AF 50 antibody resin. Protein-RNA binding analysis. Dissociation constants (K D s) for interactions of the dU2AF large subunit and mutant derivatives were determined by use of native gel electrophoresis. Binding reactions were performed in a volume of 10 l and contained the indicated concentrations of proteins, 0.1 nM 32 P-labeled oligonucleotide, 20 mM HEPES-NaOH (pH 7.6), 100 mM KCl, 0.2 mM EDTA, 10% glycerol, 0.5 mM DTT, 50 g of bovine serum albumin per ml, and 10 mg of heparin per ml. Incubations were continued for 1 h at 4°C. One half the reaction mixture was electrophoresed through a 4% polyacrylamide gel (60:1 ratio of acrylamide-bis-0.5ϫ Tris-Borate-EDTA [pH 8.3]) at 4°C for 100 min at 20 V/cm. RNA binding was quantitated with the use of the Fuji Phosphorimager, and K D s were obtained from protein concentrations at which 50% of MINX RNA was bound (10) . The MINX RNA sequence is shown in Fig. 5B .
Genetic analysis of dU2AF 50 interaction mutants. Germ line transformation of HA-tagged dU2AF 50 and interaction mutant derivatives into w 1118 embryos were as described previously (28) . Twenty to thirty independent transformant lines were generated for each mutant, and all autosomal insertion lines were tested for complementation of the recessive lethal dU2AF 50 Immunoblot analysis. Five adult flies were mashed in a microcentrifuge tube with a blue pestle homogenizer in 100 l of sodium dodecyl sulfate (SDS) sample buffer and boiled for 3 min to create a whole-fly extract. One-eighth fly equivalent was subjected to electrophoresis through an SDS-10% polyacrylamide gel, transferred to nitrocellulose, and blocked in 5% nonfat milk in phosphatebuffered saline-0.5% Tween-20. The blocked membrane was probed with affinity-purified anti-dU2AF 50 or anti-HA antibodies. Primary antibody was detected with horseradish peroxidase-conjugated goat, anti-rabbit (for anti-dU2AF 50 ) or anti-mouse (for anti-HA) immunoglobulin G with enhanced chemiluminescence detection kit as described by the manufacturer (Pierce).
The anti-dU2AF 38 and anti-dU2AF 50 polyclonal antibodies were generated in rabbits with recombinant (his) 6 -tagged dU2AF 38 and (his) 6 -tagged dU2AF 50 E. coli-expressed proteins as previously described (11) . Affinity purification was as described previously (9) . Affinity-purified, anti-dU2AF 50 antibody was diluted 50,000-fold before incubation. The affinity-purified anti-dU2AF 38 was diluted 10,000-fold before incubation. The anti-HA monoclonal antibody (16B12) (Babco) was diluted 1,000-fold before incubation.
Coimmunoprecipitation of U2AF heterodimers. Coimmunoprecipitations were performed in 0-to 12-h embryo extracts. Embryos were dechorionated in 50% bleach for 2 min, washed thoroughly with H 2 O followed by 0.05% NP-40, and transferred to microcentrifuge tubes. All subsequent manipulations were performed at 4°C. A total of 100 to 200 l of embryos was homogenized in 500 l of lysis buffer (1 M NaCl, 20 mM HEPES-NaOH [pH 7.6], 0.05% NP-40, 0.5 mM PMSF, 0.5 mM EGTA, 0.5 mM EDTA, 0.05 mM DTT, 1ϫ protease inhibitors) in a 2-ml homogenizer (B pestle). Extracts were transferred to microcentrifuge tubes and spun for 10 min. The supernatant was precleared with formalin-fixed Staphylococcus aureus cells, divided into 100-l aliquots, and incubated overnight with anti-HA (12CA5) or control (anti-KP [Drosophila P element]) antibody bound to protein A trisacryl beads (Pierce). The beads were pelleted, and the immunoprecipitate was washed three times with lysis buffer and resuspended in 25 l of SDS sample buffer. One-fifth of the pellet was analyzed by immunoblot analysis with affinity-purified anti-dU2AF 38 and anti-dU2AF 50 antibodies as described above.
RESULTS

Purification of recombinant heterodimers from E. coli requires coexpression.
In an attempt to purify recombinant Drosophila U2AF heterodimers for biochemical analysis, the large and small subunits were separately expressed and purified from E. coli. Although these proteins exist in a tight complex in nuclear extract, we were unable to reconstitute heterodimers from purified recombinant subunits even after denaturation and step renaturation (see Materials and Methods). We reasoned that association of the two subunits might require coexpression. Coexpression of proteins in tissue culture cells has been used successfully for purification of other multimeric complexes (25) . Our initial attempts at coexpression of the two U2AF subunits in E. coli by cotransformation of two independent expression plasmids resulted in variable expression and plasmid loss (data not shown). To circumvent the problem of plasmid incompatibility in E. coli (12), we developed two coexpression systems (Fig. 1) . In the first, the large-and smallsubunit cDNAs were placed under the control of two independent T7 promoters in a single dimeric plasmid (Fig. 1A) . Expression of the two subunits in this system was stoichiometric ( Fig. 2A, lanes 1, 2, 4, and 12 ). In the second coexpression system, the two subunits were placed in a bicistron under the control of a single T7 promoter (Fig. 1B) . Although expression of the large subunit was much higher than that of the small subunit in this context (Fig. 4A, lanes 2, 3, and 4) , subcloning mutant fragments into this expression vector was much more facile than subcloning mutant fragments into the dimeric plasmid used in the first coexpression system. Both vectors were used in this work. In both expression systems, a (his) 6 tag was fused to the amino terminus of one of the two U2AF subunits. Recombinant Drosophila or human U2AF heterodimers could be purified by Ni 2ϩ -NTA-agarose chromatography (Fig. 2,  lanes 3 and 13 and Fig. 4, lane 4) . The heterodimer species could be purified away from the excess free (his) 6 -tagged monomer large subunit by cation-exchange chromatography (data not shown; see Materials and Methods). The stoichiometry of the recombinant heterodimers was confirmed by analytical gel filtration chromatography (see Materials and Meth-FIG. 1. Coexpression plasmids used to purify recombinant U2AF heterodimers. (A) Two independent phage T7 promoters (indicated by arrows) were fused to the large and small U2AF subunits. Only one of the two subunits is (his) 6 -tagged (his). This expression plasmid is a dimeric plasmid containing two selectable markers, ampicillin resistance (amp) and kanamycin resistance (kan), and two origins of replication (ori). (B) A single phage T7 promoter was fused to a bicistron containing both U2AF subunits. Only one of the two subunits is (his) 6 tagged. ods). The biochemical characterization of these recombinant U2AF heterodimers will be described elsewhere (21d) .
Identification of the dU2AF 50 interaction domain. Using the dimeric plasmid coexpression system, we mapped the interaction domain on the Drosophila U2AF large subunit. Deletions in (his) 6 -tagged dU2AF 50 were coexpressed with full-length dU2AF 38 and assayed for interaction by copurification on Ni 2ϩ -NTA-agarose. Deletion of the RS domain (amino acids 1 to 34) on dU2AF 50 had no effect on copurification of dU2AF 38 ( Fig. 2A, lane 5) . However, a deletion of the 28-amino-acid linker between the RS domain and the first RNA binding domain of dU2AF 50 completely disrupted interaction with dU2AF 38 ( Fig. 2A, lane 7) . This 28-amino-acid fragment, when fused to a (his) 6 tag, efficiently copurified the small subunit ( Fig. 2A, lane 11) . Thus, the linker between the dU2AF 50 RS domain and RNA binding domains is both necessary and sufficient for interaction with dU2AF 38 (Fig. 2B) . Our findings are consistent with and further refine the interaction domain determined for hU2AF 65 by the yeast two-hybrid interaction assay (7). This domain is the most highly conserved part of the human and Drosophila large-subunit proteins (10) and is highly conserved in the U2AF large-subunit homologs from S. pombe (18) and Caenorhabditis elegans (38) (Fig. 3) .
Identification of point mutations in dU2AF 50 that disrupt heterodimer formation in vitro. To identify residues in dU2AF 50 that are important for heterodimer formation, we scanned the 28-amino-acid linker for mutations that disrupt interaction with dU2AF 38 . Since association of the U2AF subunits is resistant to high-salt conditions (35), we focused on highly conserved, hydrophobic residues in the interaction domain. Four triple-alanine-substitution mutations were created (Fig. 3) and tested for copurification of dU2AF 38 with the bicistronic copurification assay. Mutant 1 (W44A, D45A, and V46A) completely abolished interaction with the small subunit (Fig. 4A, compare lanes 4 and 5) . Since dU2AF 38 is expressed at substoichiometric levels in the bicistron coexpression plas-
FIG. 2. Mapping the domain on dU2AF
50 that is necessary and sufficient for interaction with dU2AF 38 . (A) An SDS-12% polyacrylamide gel of dU2AF 50 wild-type and deletion mutant proteins stained with Coomassie blue. U2AF subunits were coexpressed in E. coli with the dimeric coexpression plasmid. dU2AF 50 was (his) 6 tagged (His-dU2AF 50 ) in the dU2AF heterodimer, and hU2AF 35 was (his) 6 tagged in the hU2AF heterodimer (His-hU2AF 35 ). dU2AF heterodimer formation was assessed by copurification of dU2AF 38 on Ni 2ϩ -NTA-agarose. E. coli lysates from uninduced (Ϫ) and induced (ϩ) cells as well as the eluate (EL) from Ni 2ϩ -NTAagarose purification are shown. The position of dU2AF 38 is indicated by an arrow. dU2AF 38 runs heterogeneously due to carboxyl-terminal proteolysis. The identity of these polypeptides as dU2AF 38 was confirmed by immunoblot analysis (data not shown; Fig. 4A and B) . A similar heterogeneity was observed when an amino-terminal (his) 6 -tagged dU2AF 38 mid and is difficult to visualize by SDS-polyacrylamide gel electrophoresis (Fig. 4A) , we analyzed copurification of the small subunit by immunoblot with anti-dU2AF 38 antibodies (Fig. 4B and C) . No dU2AF 38 was found to copurify with mutant 1 with this more sensitive assay (Fig. 4B , compare lanes 4 and 5). Even though mutants 2 (P48A, P49A, and F51A), 3 (F51A, E52A, and I54A), and 4 (M57A, Y59A, and K60A) all have substitutions of highly conserved residues for alanine, none had a detectable effect on heterodimer formation in E. coli (Fig. 4C, compare lanes 6 to 9) . All mutant plasmids expressed approximately equal levels of dU2AF 38 and the dU2AF 50 mutant proteins ( Fig. 4A and B, compare lanes 2 and 3, and 4C, compare lanes 2 to 5, and data not shown).
It was possible that the failure of the interaction domain (linker) deletion mutant and mutant 1 to associate with the small subunit was due to misfolding of the dU2AF 50 protein. To assess whether the interaction mutants were affecting the global folding of the dU2AF 50 protein, we assayed the recombinant mutant dU2AF 50 monomers for RNA binding, since the three RNA binding domains of U2AF make up the majority of the protein and are required for RNA binding (11, 36) . The dU2AF 50 monomers were separated from the dU2AF heterodimers by ion-exchange chromatography (Fig. 5C , see Materials and Methods), and RNA binding activity was determined by electrophoretic mobility shift analysis (Fig. 5A) . The purified, recombinant proteins were incubated for 1 h at various protein concentrations with a 32 P-labeled pyrimidine tract RNA oligonucleotide derived from the adeno L1-L2 intron (MINX). The sequence of the MINX pyrimidine tract is shown in Fig. 5B . The four triple-alanine point mutants and the interaction domain deletion mutant all bound the MINX pyrimidine tract with comparable affinity to wild-type dU2AF 50 . In particular, the dissociation constant of mutant 1 was within 15% of wild-type dU2AF 50 (see legend for Fig. 5 ). We conclude that the dU2AF 50 point mutations and the deletion mutation do not effect the global folding of the dU2AF 50 protein as assessed by the ability of the soluble, mutant proteins to bind polypyrimidine tract RNA.
U2AF heterodimer formation is essential in vivo. If U2AF heterodimer formation is required in vivo, then a dU2AF 50 mutant that is incapable of interacting with dU2AF 38 should fail to complement a recessive lethal dU2AF 50 mutation (11, 21) . To test the requirement for heterodimer formation in vivo, the triple-alanine mutations were introduced into an HA epitope-tagged dU2AF 50 transformation vector. The dU2AF 50 transgene was epitope tagged to assess expression levels of the mutant proteins in the presence of endogenous dU2AF 50 and to analyze heterodimer formation in embryo extracts (see below). The wild-type, HA-tagged dU2AF 50 transgene rescues dU2AF 50 mutant flies as efficiently as an untagged transgene ( Fig. 6 and unpublished data) . A total of 20 to 30 independent transformant lines of each mutant were generated by P element-mediated germ line transformation. All autosomal insertion lines were tested for the ability to complement a recessive lethal dU2AF 50 allele. Balanced, heterozygous dU2AF 50 mutant females were crossed to males carrying a dU2AF 50 transgene. The viability of hemizygous, dU2AF 50 mutant male progeny carrying the dU2AF 50 transgene was compared to the viability of their unbalanced sisters. Consistent with the ability of mutants 2 and 3 to interact with dU2AF 38 in our copurification assay, ϳ50% of the dU2AF 50 transgene lines that contained these alanine substitution mutations rescued the recessive lethal dU2AF 50 allele (see Materials and Methods), and several lines of each mutant could be maintained as stocks in which their sole source of dU2AF 50 was the mutant transgene. The average rescues for the mutant 2 and 3 rescuing lines were 67 and 41%, respectively (Fig. 6) . The expression levels of the mutant proteins in these transgenic lines were assessed by immunoblot analysis with anti-dU2AF 50 and anti-HA antibodies. The mutant protein levels were similar to or lower than the levels in the wild-type, HA-tagged, dU2AF 50 transgene lines (Fig. 7, compare lanes 2, 6 , and 8 and data not shown).
Mutant 4 had no detectable effect on heterodimer formation in our copurification assay; yet, none of the 12 independent mutant 4 transgene lines tested were capable of rescuing the recessive lethal dU2AF 50 allele. The protein expression levels in these transgene lines were similar to the levels found in rescuing mutant 2 and 3 transgene lines (Fig. 7 , compare lane 4 to lanes 6 and 8 and data not shown). To determine whether higher mutant 4 protein levels were required for complementation, independent mutant 4 transgenes were combined and tested for complementation of the dU2AF 50 recessive lethal allele (see Materials and Methods). When the mutant 4 transgene dose was doubled, complementation of the dU2AF 50 mutant allele was observed. The average rescue when two mutant 4 transgenes were combined was 11% (Fig. 6) .
Consistent with the complete disruption of heterodimer formation, mutant 1 was completely incapable of complementing the dU2AF 50 recessive lethal allele (Fig. 6) . No rescue was observed in the 13 independent mutant 1 transgene lines tested. The mutant 1 protein levels in these transgene lines were similar to mutant 2 and 3 transgene lines that were capable of complementing the dU2AF 50 mutant (Fig. 7 , compare lane 5 to lanes 6 and 8 and data not shown). To rule out the   FIG. 4 . Identification of point mutations that disrupt heterodimer formation in vitro. (his) 6 -tagged dU2AF 50 or dU2AF 50 interaction mutant derivatives were coexpressed with dU2AF 38 with the bicistronic coexpression plasmid. Heterodimer formation was assessed by copurification of dU2AF 38 on Ni 2ϩ -NTAagarose. E. coli lysates from uninduced (Ϫ) and induced (ϩ) cells and the eluate (EL) from Ni 2ϩ -NTA-agarose purification were electrophoresed on an SDS-10% polyacrylamide gel and stained with Coomassie blue (A) or transferred to nitrocellulose and probed with affinity-purified anti-dU2AF 38 antibodies (B and C). The position of dU2AF 38 is indicated with an arrow. Molecular size markers are indicated in kilodaltons.
possibility that the mutant 1 protein levels were not high enough to rescue the dU2AF 50 mutant allele, three transgene lines that expressed high levels of mutant 1 protein were combined in pairwise combinations and tested for complementation. Increasing the mutant 1 transgene dose still failed to restore viability to the dU2AF 50 mutants (data not shown). Interaction mutants are impaired in heterodimer formation in embryo extracts. To assess whether the dU2AF 50 point mutations were affecting heterodimer formation in vivo, we analyzed U2AF subunit association in embryo extracts. Embryos (0-to 12-h) were collected from w 1118 (dU2AF 50ϩ
